Table 2 Overall response rate

From: Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study

 

ITT patients ( n =49)

Evaluable patients ( n =44)

Overall response

N

(%)

N

(%)

Complete response

2

(4.1)

2

(4.6)

Partial response

23

(46.9)

22

(50.0)

Response rate (CR+PR)

25

(51.0)

24

(54.5)

No change

17

(34.7)

16

(36.4)

Progressive disease

4

(8.2)

4

(9.1)

Nonevaluable

3

(6.1)

’

’

  1. ITT=intent to treat; CR=complete response; PR=partial response.
Back to article page